Human Umbilical Vein Smooth Muscle Cells: HUVSMC, neonatal

Lot specific orders are not able to be placed through the web. Contact your local sales rep for more details.

HUVSMC has been used in studies evaluating treatments that involve blood vessel stents. Specifically, intra-shunt delivery of motexafin gadolinium was shown to inhibit the proliferation of SMCs during treatment of portal hypertension (Wang, 2013). Also, high-density lipoproteins (HDL) exhibit cardioprotective and anti-inflammatory properties by reducing HUVSMC expression of chemokines CCL2, CCL5, and CX3CL1, and chemokine receptors CCR2 and CX3CR1 (via NF-κB/pAkt inhibition) and by decreasing cell proliferation (via pERK inhibition), highlighting HDL importance in preventing neointimal hyperplasia, the main cause of early vein graft/stent failure (van der Vorst, 2013). HUVSMC were also used to demonstrate that genes coding for muscle and non-muscle actin proteins are transcribed by different transcription machinery (Lee, 2011).Characterization: positive for smooth muscle cell specific alpha-actin expression.

Vein

cell adhesion, pharmacology, vascular therapy research, coagulation, drug discovery, regulation of vascular tone

Smooth Muscle Cell Basal Medium containing 10% FBS & 10% DMSO

Please refer to the HUVSMC Culture Protocol.

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.